{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:42:50Z","timestamp":1773812570967,"version":"3.50.1"},"reference-count":24,"publisher":"Georg Thieme Verlag KG","issue":"07","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nBackground The long-acting somatostatin analog lanreotide autogel is effective in the treatment of patients with neuroendocrine tumors.<\/jats:p><jats:p>\nObjective To evaluate the long-term treatment response in patients with neuroendocrine tumors receiving lanreotide autogel in routine clinical practice.<\/jats:p><jats:p>\nMethods Non-interventional, 24-month study in patients with neuroendocrine tumors treated with lanreotide autogel (NCT01840449).<\/jats:p><jats:p>\nResults Patients (n=80) from 26 centers in Germany and Austria were enrolled. Neuroendocrine tumors were mainly grade 1\/2, metastasized, intestinal, and associated with carcinoid syndrome; 88.9% had received previous neuroendocrine tumor treatment. Of those, 84.4% had previous surgery, 18.7% had received octreotide. The primary endpoint, defined by a &lt;50% chromogranin A increase at month 12 compared with the lowest value between baseline and month 3 was achieved by 89.5% patients. Stable disease according to Response Evaluation Criteria in Solid Tumors 1.1 was observed in 76.9 and 75.0% patients at months 12 and 24 of lanreotide treatment, respectively. Mean change of chromogranin A levels from baseline to month 24 was \u22120.12 \u00d7 upper limit of normal (95% CI, \u22120.22; \u22120.45). In a post hoc analysis, 38.5% of the subgroup of patients with carcinoid syndrome had daily diarrhea at baseline vs. 21.4% at month 24. At baseline, 27.8% of patients received lanreotide 120\u2009mg every 4 weeks vs. 56.7% at month 24. Quality of life data were heterogeneous. No new safety issues arose and\/or required further investigation.<\/jats:p><jats:p>\nConclusions Our study reflects routine lanreotide autogel use in patients with advanced\/metastatic neuroendocrine tumors. This analysis shows effectiveness with stabilization of disease-related symptoms and good tolerability of lanreotide autogel in clinical practice.<\/jats:p>","DOI":"10.1055\/a-1342-2755","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T23:03:06Z","timestamp":1626994986000},"page":"500-509","source":"Crossref","is-referenced-by-count":5,"title":["Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria"],"prefix":"10.1055","volume":"129","author":[{"given":"Anja","family":"Rinke","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Endocrinology, University Hospital Gie\u00dfen and Marburg, Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Maintz","sequence":"additional","affiliation":[{"name":"H\u00e4matologisch-Onkologische Praxis, MVZ West GmbH, W\u00fcrselen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Onkologie Unter-Ems, Leer, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias M.","family":"Weber","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Medicine 1, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Lahner","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, Division of Laboratory Research, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Pavel","sequence":"additional","affiliation":[{"name":"Department of Medicine 1, Division of Endocrinology, Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Saeger","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Pituitary Pathologist, University Hospital Eppendorf, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Houchard","sequence":"additional","affiliation":[{"name":"Ipsen, Boulogne Billancourt, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Ungewiss","sequence":"additional","affiliation":[{"name":"Ipsen, M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Petersenn","sequence":"additional","affiliation":[{"name":"ENDOC Center for Endocrine Tumors, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"A Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mdq290","article-title":"Gastrointestinal neuroendocrine tumors","volume":"21","author":"K E Oberg","year":"2010","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"M Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000381930","article-title":"Carcinoid Heart Disease: From Pathophysiology to Treatment\u2013'Something in the Way It Moves\u2019","volume":"101","author":"S Grozinsky-Glasberg","year":"2015","journal-title":"Neuroendocrinology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"Evaluation of lanreotide depot\/Autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): A randomized, double-blind, placebo-controlled trial","volume":"22","author":"A I Vinik","year":"2016","journal-title":"Endocr Pract"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"D O'Toole","year":"2000","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4158\/EP172000.OR","article-title":"Lanreotide therapy in carcinoid syndrome: prospective analysis of patient-reported symptoms in patients responsive to prior octreotide therapy and patients naive to somatostatin analogue therapy in the ELECT phase 3 study","volume":"24","author":"G A Fisher","year":"2018","journal-title":"Endocr Pract"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.dld.2015.12.013","article-title":"Patient-reported outcomes with lanreotide Autogel\/Depot for carcinoid syndrome: An international observational study","volume":"48","author":"P Ruszniewski","year":"2016","journal-title":"Dig Liver Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoid syndrome: Results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"P Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"M E Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1530\/ERC-15-0490","article-title":"Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: The CLARINET open-label extension study","volume":"23","author":"M E Caplin","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11523-016-0440-y","article-title":"Safety and QOL in patients with Advanced NET in a phase 3b expanded access study of everolimus","volume":"11","author":"M Pavel","year":"2016","journal-title":"Target Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"D Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JGO.2015.002980","article-title":"Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs","volume":"3","author":"S Singh","year":"2017","journal-title":"J Glob Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000488510","article-title":"Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic neuroendocrine tumours","volume":"107","author":"R Basuroy","year":"2018","journal-title":"Neuroendocrinology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1677\/erc.0.0100451","article-title":"Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours","volume":"10","author":"W W de Herder","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1749-6632.1994.tb17262.x","article-title":"Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues","volume":"733","author":"J C Reubi","year":"1994","journal-title":"Ann NY Acad Sci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.3748\/wjg.v10.i24.3628","article-title":"Scintigraphic detection of carcinoid tumors with a cost effectiveness analysis","volume":"10","author":"D Dimitroulopoulos","year":"2004","journal-title":"World J Gastroenterol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.beem.2004.11.016","article-title":"Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours","volume":"19","author":"K Oberg","year":"2005","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1055\/a-0604-2924","article-title":"S2k-Leitlinie Neuroendokrine Tumore, AWMF Register Nr. 021-26","volume":"56","author":"A Rinke","year":"2018","journal-title":"Z Gastroenterol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.clinthera.2018.10.008","article-title":"Relationship between symptoms and health-related quality-of-life benefits in patients with carcinoid syndrome: Post Hoc Analyses From TELESTAR","volume":"40","author":"D Cella","year":"2018","journal-title":"Clin Ther"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/MPA.0000000000000955","article-title":"Treatment patterns and clinical outcomes in patients with metastatic gastroenteropancreatic neuroendocrine tumors treated in the community practice setting in the United States","volume":"47","author":"X Jiao","year":"2018","journal-title":"Pancreas"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: An endocrine society clinical practice guideline","volume":"99","author":"L Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000471880","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: Systemic therapy - biotherapy and novel targeted agents","volume":"105","author":"M Pavel","year":"2017","journal-title":"Neuroendocrinology"}],"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1342-2755.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T23:03:19Z","timestamp":1626994999000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1342-2755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":24,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2021,7,19]]},"published-print":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1342-2755","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}